Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) EPS (Weighted Average and Diluted) (2016 - 2025)

Avalo Therapeutics filings provide 10 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.37 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 121.51% to -$0.37 in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.73, a 96.33% increase, with the full-year FY2025 number at -$5.84, up 72.07% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.37 in Q4 2025 for Avalo Therapeutics, up from -$2.19 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $117.47 in Q4 2023 to a low of -$1059.6 in Q4 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$2.1 (2021), compared with a mean of -$74.34.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 116.27% in 2022, down 54802.07% in 2022.
  • Avalo Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.93 in 2021, then tumbled by 54802.07% to -$1059.6 in 2022, then surged by 111.09% to $117.47 in 2023, then crashed by 98.54% to $1.72 in 2024, then tumbled by 121.51% to -$0.37 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.37 (Q4 2025), -$2.19 (Q3 2025), and -$1.92 (Q2 2025) per Business Quant data.